Baseline | Follow up | End of study | ||
---|---|---|---|---|
Participants (n) | 102 | 89 | 82 | |
Total exit from study (n) | - | 13 | 20 | |
Technically successful study (n) | 102 (100%) | 80 (90%) | 78 (95%) | |
Age (years) | 38 ± 11 | 41 ± 11 | 43.0 ± 10 | |
Follow up time (years) | - | 2.4 ± 0.4 | 4.8 ± 0.5 | |
Body surface area (m2) | 1.5 ± 0.2 | 1.5 ± 0.2 | 1.5 ± 0.1 | |
Karyotype (45,X/other) | 58%/42% | 60%/40% | 61%/39% | |
Oestrogen replacement therapy | 86% | 85% | 82% | |
Antihypertensive treatment | 29% | 28% | 55% | |
Statin treatment | 6% | 9% | 13% | |
Diabetes | 5% | 8% | 12% | |
Previous growth hormone treatment | 27% | 26% | 22% | |
Ambulatory blood pressure | ||||
24-hour systolic (mm Hg) | 122 ± 14 | 122 ± 14 | 117 ± 13 | |
24-hour diastolic (mm Hg) | 77 ± 11 | 78 ± 11 | 75 ± 8 | |
24-hour heart rate (beats/min) | 76 ± 10 | 77 ± 9 | 74 ± 9 | |
Aortic dimensions (mm) | ||||
Aortic sinus | 29.1 ± 4.0 | 29.2 ± 3.0 * | 31.0 ± 4.4 * | |
Sinotubular junction | 25.4 ± 4.7 | 25.3 ± 4.3 | 26.3 ± 4.6 * | |
Mid-ascending aorta | 27.4 ± 6.7 | 27.5 ± 5.0 | 28.6 ± 5.2 * | |
Distal ascending aorta | 25.4 ± 4.0 | 25.5 ± 3.6 | 25.8 ± 3.7 | |
Proximal aortic arch | 23.5 ± 3.7 | 23.4 ± 3.6 | 23.9 ± 3.5 | |
Mid aortic arch | 20.5 ± 2.6 | 20.5 ± 2.7 | 20.7 ± 2.6 | |
Distal transverse aortic arch | 19.3 ± 2.4 | 19.3 ± 2.3 | 19.4 ± 2.3 | |
Proximal descending | 19.4 ± 2.9 | 19.5 ± 2.8 | 19.8 ± 3.4 | |
Distal descending aorta | 18.2 ± 2.4 | 18.2 ± 2.2 | 18.3 ± 2.5 | |
Aortic valve and aortic anomalies | ||||
Bicuspid aortic valve | 25% | 28% | 30% | |
Aortic stenosis † | 12% (7%/4%/1%) | 11% (8%/3%/-) | 13% (9%/4%/-) | |
Aortic regurgitation † | 22% (16%/5%/1%) | 21% (18%/3%/-) | 23% (17%/5%/1%) | |
Elongated transverse aortic arch | 47% | 48% | 48% | |
Aortic coarctation ‡ | 12% | 11% | 10% |